HIV, Pregnancy
Conditions
Keywords
Prevention of mother-to-child transmission (PMTCT) services, maternal viral load monitoring, early infant diagnosis (EID), Kenya, perinatal HIV transmission
Brief summary
The goal of this project is to rigorously evaluate the efficacy of HIV Infant Tracking System 2.1 (HITSystem, an eHealth intervention that uses short message service (SMS) texts to patients and algorithm-driven electronic alerts for providers) to increase retention in guideline-adherent prevention of mother-to-child transmission of HIV services (PMTCT) and to increase viral suppression and appropriate clinical action through the extended period of 6 months postpartum, compared to standard of care PMTCT services in a matched, cluster randomized controlled trial.
Detailed description
Despite progress in providing comprehensive prevention of mother-to-child transmission of HIV (PMTCT) services, significant gaps in the timely uptake and provision of guideline-adherent services and maternal retention in care remain. Such gaps create missed opportunities for preventing mother-to-child transmission and result in nearly 6,100 infants becoming infected with HIV each year in Kenya. Effective interventions that routinize the delivery of evidence-based PMTCT services and foster consistent patient engagement are essential to close the remaining gaps and eliminate mother-to-child transmission of HIV. Building off of a successful R34 grant to develop and pilot test the HITSystem 2.0, an eHealth intervention targeting PMTCT services, the overall goal of this proposal is to use a cluster randomized control design at 12 Kenyan government hospitals to evaluate a modified HITSystem 2.1 intervention. HITSystem 2.1 reflects the 2018 Kenyan PMTCT guidelines, including routine viral load monitoring and interventions to suppress maternal viral load. The investigators aim to evaluate the impact of HITSystem 2.1 to optimize the provision of guideline-adherent services and viral suppression through the antenatal, delivery, and early postpartum periods. Aim 1 of the proposed study will assess the efficacy of the HITSystem 2.1 to increase the proportion of mothers who receive complete PMTCT services (including appointment attendance, medication adherence support, viral load testing, hospital-based delivery, and infant testing per Kenyan National Guidelines) through 6 months postpartum. The investigators hypothesize that mothers receiving the HITSystem 2.1 intervention will have a significantly higher completion rate for guideline-adherence PMTCT services compared to mothers receiving standard of care PMTCT services. In Aim 1b, the investigators will evaluate HITSystem 2.1 implementation using the RE-AIM model to inform sustainable scale up. Aim 2 will assess the efficacy of HITSystem 2.1 to increase viral suppression (\<1,000 copies/mL) among pregnant and postpartum women, including those who disengage from care. The investigators hypothesize that mothers at HITSystem 2.1 sites will have higher rates of viral suppression at delivery and 6 months postpartum. Aim 3 will evaluate the cost-effectiveness of the HITSystem 2.1. Driven by differences in PMTCT retention, viral suppression, and modeled estimates of pediatric HIV infections averted, the investigators hypothesize that the HITSystem 2.1 will be cost-effective, based on World Health Organization criteria. This proposal is aimed at improving the quality of PMTCT services in the health facility setting. If efficacious and cost-effective, HITSystem 2.1 holds strong promise for national dissemination.
Interventions
HITSystem 2.1 is an intervention that tracks HIV+ pregnant women and their infants to improve the completeness and efficiency of PMTCT services. Key intervention features include: (1) SMS messages sent to enrolled women and mothers to support essential PMTCT services, (2) automated, algorithm-driven alerts for providers when per-guidelines PMTCT services are missed, and (3) automatic enrollment of infants into early infant diagnosis (EID) and linkage with maternal PMTCT file at documentation of infant birth to improve the continuum of care for HIV+ mothers and HIV-exposed infants. The HITSystem 2.1 intervention aims to facilitate complete PMTCT retention and viral load (VL) monitoring with prompt clinical action (adherence support, antiretroviral therapy (ART) regimen change) in the antenatal, delivery, and 6-month postpartum periods to increase viral suppression during windows critical for HIV prevention.
Sponsors
Study design
Intervention model description
Matched, cluster randomized controlled design
Eligibility
Inclusion criteria
* Pregnant women living with HIV who present for care at one of the study hospitals by 36 weeks gestation and provide written informed consent are eligible for enrollment in the study.
Exclusion criteria
* Pregnant women living with HIV will be excluded from study participation if she has any condition (including drug abuse, alcohol abuse, or psychiatric disorder) that study or hospital staff feel precludes her from providing informed consent. * Women who transfer care from one study site to another during their PMTCT services will be ineligible for enrollment at their new facility.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Receiving Complete PMTCT | 7-15 months (PMTCT enrollment date through 6 months postpartum) | documented receipt of all of the following: maternal ART initiation, antenatal appointment attendance, facility delivery, EID linkage by 7 weeks of age, maternal viral load testing and clinical action per national guidelines through 6 months postpartum (Table 6). Participants who receive all indicated services per guidelines will be coded as 1 or 'yes'. Participants missing \> 1 service will be coded as 0 or incomplete PMTCT services. |
| Viral Suppression | 1-9 months | Number of clients with a suppressed viral load(\<1000 copies/mL) at delivery |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PMTCT Retention Duration (Weeks) | 7-15 months (PMTCT enrollment date through 6 months postpartum) | The number of weeks women were engaged in PMTCT services |
| Antenatal Viral Load (VL) Test Coverage | Within one month of enrollment in PMTCT | The number of women receiving viral load testing upon enrolling in prevention of mother to child transmission of HIV services (PMTCT). |
| Turnaround Time of Viral Load Sample Collection to Patient Notification | PMTCT enrollment date through 6 months postpartum | The median number of days from the date of VL sample collection to patient notification, among all viral load tests |
| Viral Load Test Utility | PMTCT enrollment date through 6 months postpartum | Number of detectable viral load results with clinical action per guidelines, such as: intensified adherence counseling and/or ARV regimen change |
| Postnatal Viral Load (VL) Test Coverage | Between delivery and 7 months postpartum | The number of women receiving postpartum viral load testing per the Kenyan national guidelines. |
| Antiretroviral Therapy (ART) Adherence | 7-15 months (PMTCT enrollment date through 6 months postpartum) | The number of participants with ART adherence \> 95% |
Countries
Kenya
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Intervention Arm (HITSystem 2.1) Participants enrolled at intervention sites will received HITSystem 2.1-supported PMTCT services through 6 months postpartum. Interventions received will include: text messages to patients to support medication adherence, appointment attendance, and hospital delivery and algorithm-driven alerts to notify providers when follow up services are missed.
HITSystem 2.1: HITSystem 2.1 is an intervention that tracks HIV+ pregnant women and their infants to improve the completeness and efficiency of PMTCT services. Key intervention features include: (1) SMS messages sent to enrolled women and mothers to support essential PMTCT services, (2) automated, algorithm-driven alerts for providers when per-guidelines PMTCT services are missed, and (3) automatic enrollment of infants into early infant diagnosis (EID) and linkage with maternal PMTCT file at documentation of infant birth to improve the continuum of care for HIV+ mothers and HIV-exposed infants. The HITSystem 2.1 intervention aims to facilitate complete PMTCT retention and viral load (VL) monitoring with prompt clinical action (adherence support, antiretroviral therapy (ART) regimen change) in the antenatal, delivery, and 6-month postpartum periods to increase viral suppression during windows critical for HIV prevention. | 767 |
| Control Arm (Standard of Care) Participants enrolled at control sites will receive standard of care PMTCT services, with no HITSystem 2.1 tracking or follow up. | 627 |
| Total | 1,394 |
Baseline characteristics
| Characteristic | Control Arm (Standard of Care) | Intervention Arm (HITSystem 2.1) | Total |
|---|---|---|---|
| Age, Continuous | 30.4 years STANDARD_DEVIATION 6 | 30.6 years STANDARD_DEVIATION 5.8 | 30.5 years STANDARD_DEVIATION 5.9 |
| Education level Beyond secondary education | 41 Participants | 43 Participants | 84 Participants |
| Education level Completed secondary education | 74 Participants | 112 Participants | 186 Participants |
| Education level Less than secondary education | 508 Participants | 611 Participants | 1119 Participants |
| Education level Missing | 4 Participants | 1 Participants | 5 Participants |
| Gestational week at enrollment | 19.9 weeks STANDARD_DEVIATION 7.3 | 19.1 weeks STANDARD_DEVIATION 7.8 | 19.5 weeks STANDARD_DEVIATION 7.6 |
| HIV disclosure Anyone | 535 Participants | 676 Participants | 1211 Participants |
| HIV disclosure Missing | 3 Participants | 1 Participants | 4 Participants |
| HIV disclosure No one | 89 Participants | 90 Participants | 179 Participants |
| Household income <750 KSh | 224 Participants | 268 Participants | 492 Participants |
| Household income >=750 KSH | 257 Participants | 336 Participants | 593 Participants |
| Household income Missing | 146 Participants | 163 Participants | 309 Participants |
| Partner living situation Live separate from partner | 104 Participants | 128 Participants | 232 Participants |
| Partner living situation Live with current partner | 459 Participants | 581 Participants | 1040 Participants |
| Partner living situation Missing | 6 Participants | 6 Participants | 12 Participants |
| Partner living situation No current partner | 58 Participants | 52 Participants | 110 Participants |
| Past experience with prevention of mother to child transmission(PMTCT)/early infant diagnosis (EID) No | 272 Participants | 290 Participants | 562 Participants |
| Past experience with prevention of mother to child transmission(PMTCT)/early infant diagnosis (EID) Yes | 355 Participants | 477 Participants | 832 Participants |
| Race and Ethnicity Not Collected | — | — | 0 Participants |
| Region of Enrollment Kenya | 627 participants | 767 participants | 1394 participants |
| Sex: Female, Male Female | 627 Participants | 767 Participants | 1394 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
| Time of antiretroviral treatment (ART) initiation >5 years prior to current pregnancy | 232 Participants | 274 Participants | 506 Participants |
| Time of antiretroviral treatment (ART) initiation <5 yrs prior to current pregnancy | 228 Participants | 331 Participants | 559 Participants |
| Time of antiretroviral treatment (ART) initiation During current pregnancy | 145 Participants | 162 Participants | 307 Participants |
| Time of antiretroviral treatment (ART) initiation Missing | 22 Participants | 0 Participants | 22 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 14 / 899 | 22 / 740 |
| other Total, other adverse events | 0 / 899 | 0 / 740 |
| serious Total, serious adverse events | 41 / 899 | 41 / 740 |
Outcome results
Number of Participants Receiving Complete PMTCT
documented receipt of all of the following: maternal ART initiation, antenatal appointment attendance, facility delivery, EID linkage by 7 weeks of age, maternal viral load testing and clinical action per national guidelines through 6 months postpartum (Table 6). Participants who receive all indicated services per guidelines will be coded as 1 or 'yes'. Participants missing \> 1 service will be coded as 0 or incomplete PMTCT services.
Time frame: 7-15 months (PMTCT enrollment date through 6 months postpartum)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention Arm (HITSystem 2.1) | Number of Participants Receiving Complete PMTCT | 60 Participants |
| Control Arm (Standard of Care) | Number of Participants Receiving Complete PMTCT | 22 Participants |
Viral Suppression
Number of clients with a suppressed viral load(\<1000 copies/mL) at delivery
Time frame: 1-9 months
Population: The overall number of participants analyzed include only those who had a documented viral load test at delivery.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention Arm (HITSystem 2.1) | Viral Suppression | 655 Participants |
| Control Arm (Standard of Care) | Viral Suppression | 535 Participants |
Antenatal Viral Load (VL) Test Coverage
The number of women receiving viral load testing upon enrolling in prevention of mother to child transmission of HIV services (PMTCT).
Time frame: Within one month of enrollment in PMTCT
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention Arm (HITSystem 2.1) | Antenatal Viral Load (VL) Test Coverage | 330 Participants |
| Control Arm (Standard of Care) | Antenatal Viral Load (VL) Test Coverage | 137 Participants |
Antiretroviral Therapy (ART) Adherence
The number of participants with ART adherence \> 95%
Time frame: 7-15 months (PMTCT enrollment date through 6 months postpartum)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention Arm (HITSystem 2.1) | Antiretroviral Therapy (ART) Adherence | 466 Participants |
| Control Arm (Standard of Care) | Antiretroviral Therapy (ART) Adherence | 200 Participants |
PMTCT Retention Duration (Weeks)
The number of weeks women were engaged in PMTCT services
Time frame: 7-15 months (PMTCT enrollment date through 6 months postpartum)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention Arm (HITSystem 2.1) | PMTCT Retention Duration (Weeks) | 48.4 weeks | Standard Deviation 9.6 |
| Control Arm (Standard of Care) | PMTCT Retention Duration (Weeks) | 47.2 weeks | Standard Deviation 8.1 |
Postnatal Viral Load (VL) Test Coverage
The number of women receiving postpartum viral load testing per the Kenyan national guidelines.
Time frame: Between delivery and 7 months postpartum
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention Arm (HITSystem 2.1) | Postnatal Viral Load (VL) Test Coverage | 518 Participants |
| Control Arm (Standard of Care) | Postnatal Viral Load (VL) Test Coverage | 371 Participants |
Turnaround Time of Viral Load Sample Collection to Patient Notification
The median number of days from the date of VL sample collection to patient notification, among all viral load tests
Time frame: PMTCT enrollment date through 6 months postpartum
Population: Turnaround time was measured among all viral load samples taken in the antenatal and/or postpartum periods.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Intervention Arm (HITSystem 2.1) | Turnaround Time of Viral Load Sample Collection to Patient Notification | 35 days |
| Control Arm (Standard of Care) | Turnaround Time of Viral Load Sample Collection to Patient Notification | 35 days |
Viral Load Test Utility
Number of detectable viral load results with clinical action per guidelines, such as: intensified adherence counseling and/or ARV regimen change
Time frame: PMTCT enrollment date through 6 months postpartum
Population: Viral load test utility was analyzed only among those participants with a detectable viral load result.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention Arm (HITSystem 2.1) | Viral Load Test Utility | 28 Participants |
| Control Arm (Standard of Care) | Viral Load Test Utility | 18 Participants |